HUM → $280.00 by May 21, 2027.

HUM (Humana Inc) Thesis Humana is trading at a deep cyclical-fear discount driven by Medicare Advantage regulatory anxiety, pricing in a worst-case margin scenario that likely overstates the actual policy risk. Over 12-18 months, if CMS rate clarity emerges and medical cost ratios normalize from post-COVID peaks, the stock could re-rate toward $260-300 range, representing 45-65% upside from current levels. Humana at $176.30 is priced at 5.7-7.2x normalized earnings and approximately 2.5x trailing operating cash flow for a business growing …